The Cash-Pay Prescription: How Direct-Pay Scripts Work Without Insurance

Cash-Pay: The Simplest Path to GLP-1 Access

The cash-pay prescription pathway eliminates insurance entirely: your prescriber writes a prescription, you pay the pharmacy directly, and no claims are filed. This is how the majority of compounded GLP-1 patients access their medication, and it's an increasingly common choice for patients whose insurance doesn't cover brand-name options.

The appeal is simplicity. No prior authorization. No step therapy. No formulary restrictions. No denial letters. No appeals. You qualify clinically, your prescriber writes the script, and you pay for the medication. The trade-off is cost: you're paying the full price with no insurance contribution.

Cash-Pay Pricing Landscape

Compounded semaglutide (injectable): $149-$399/month through telehealth platforms. Price varies by dose, provider, and billing model (monthly vs. quarterly). This is the most popular cash-pay option.

Compounded tirzepatide (injectable): $199-$449/month through telehealth platforms. Generally 20-30% more expensive than compounded semaglutide at comparable doses.

Brand-name Wegovy at retail: $1,349/month list price. Manufacturer savings programs may reduce this significantly for eligible patients.

Brand-name Zepbound at retail: $1,060/month list price. LillyDirect offers a self-pay program at reduced rates.

Compounded oral formulations: $99-$249/month for sublingual tablets, ODTs, or drops through telehealth platforms.

What You Gain and What You Lose

You gain: Speed (no PA process), simplicity (no insurance navigation), privacy (no claims on your insurance record), and choice (access to compounded formulations that insurance wouldn't cover anyway).

You lose: Insurance cost-sharing (you pay 100%), prescription tracking through your insurer's system (which can affect your deductible and out-of-pocket maximum calculations for other medications), and the consumer protections that come with insurance claims processing.

For patients with no GLP-1 insurance coverage, the cash-pay path isn't really a trade-off — it's the only option besides paying $1,000+ per month for brand-name. For patients who have coverage but face long PA timelines, some start on cash-pay compounded while pursuing insurance approval simultaneously.

Choosing the Right Cash-Pay Channel

Not all cash-pay options are equal. Here's what to evaluate: Is the telehealth platform using a licensed compounding pharmacy (503A or 503B)? Is there a medical evaluation involved, or just a questionnaire? Is the pricing all-inclusive, or are there additional fees for consultations, labs, or shipping? What's the cancellation policy — are you locked into a subscription?

Legitimate cash-pay platforms are transparent about their pharmacy partners, their prescriber credentials, their pricing, and their cancellation terms. If any of these are opaque, look elsewhere.